Zhankui M. Jia

Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Construction and validation of a nomogram model for the differential diagnosis of primary testicular benign and malignant tumors.

Construction and validation of a nomogram model for the differential diagnosis of primary testicular benign and malignant tumors.

Journal: Scientific reports

Published: December 27, 2025

Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells.

Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 21, 2025

Targeted inhibition of the CREB1-CtIP axis enhances the efficacy of abiraterone combined with radiotherapy in prostate cancer.

Targeted inhibition of the CREB1-CtIP axis enhances the efficacy of abiraterone combined with radiotherapy in prostate cancer.

Journal: Cell death & disease

Published: July 14, 2025

Integrating multimodal clinical data with a large model for prostate cancer diagnosis.

Integrating multimodal clinical data with a large model for prostate cancer diagnosis.

Journal: NPJ digital medicine

Published: July 05, 2025

Bioinformatics identifies key genes and potential therapeutic targets in the pathological mechanism of oxidative stress in Randall's plaque.

Bioinformatics identifies key genes and potential therapeutic targets in the pathological mechanism of oxidative stress in Randall's plaque.

Journal: Scientific reports

Published: September 07, 2024

Phosphatase LHPP confers prostate cancer ferroptosis activation by modulating the AKT-SKP2-ACSL4 pathway.

Phosphatase LHPP confers prostate cancer ferroptosis activation by modulating the AKT-SKP2-ACSL4 pathway.

Journal: Cell death & disease

Published: April 16, 2024

Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators.

Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators.

Journal: Cell death & disease

Published: March 01, 2024

LINC00645 inhibits renal cell carcinoma progression by interacting with HNRNPA2B1 to regulate the ROCK1 mRNA stability.

LINC00645 inhibits renal cell carcinoma progression by interacting with HNRNPA2B1 to regulate the ROCK1 mRNA stability.

Journal: Gene

Published: November 16, 2023

8-Br-cGMP activates HSPB6 and increases the antineoplastic activity of quinidine in prostate cancer.

8-Br-cGMP activates HSPB6 and increases the antineoplastic activity of quinidine in prostate cancer.

Journal: Cell death discovery

Published: September 23, 2023

TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.

TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 14, 2023

A novel risk model of three SUMOylation genes based on RNA expression for potential prognosis and treatment sensitivity prediction in kidney cancer.

A novel risk model of three SUMOylation genes based on RNA expression for potential prognosis and treatment sensitivity prediction in kidney cancer.

Journal: Frontiers in pharmacology

Published: September 07, 2022

Telomere-related gene risk model for prognosis and drug treatment efficiency prediction in kidney cancer.

Telomere-related gene risk model for prognosis and drug treatment efficiency prediction in kidney cancer.

Journal: Frontiers in immunology

Published: June 21, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026